Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on BioNTech SE (NASDAQ:BNTX) on Monday, setting a price target of $400, which is approximately 14.94% above the present share price of $348.
Shu expects BioNTech SE to post earnings per share (EPS) of $13.24 for the fourth quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in BioNTech SE, with an average price target of $293.7.
The analysts price targets range from a high of $400 to a low of $180.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $6.09 billion and a net profit of $4.56 billion. The company's market cap is $73.91 billion.
According to TipRanks.com, Berenberg Bank analyst Zhiqiang Shu is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 1.8% and a 37.78% success rate.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.